Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PREDIX HER2 Trial: Similar Efficacy, Less Toxicity with T-DM1 for HER2+, HR+ Breast Cancer

Key clinical point: T-DSM1 had similar efficacy, less toxicity vs. standard chemotherapy for HER2- and HR-positive breast cancer.

Major finding: The pCR rates were 45% and 47% with T-DM1 and DTP, respectively.

Study details: The phase 2 PREDIX HER2 trial of 199 patients.

Disclosures: Dr. Bergh reported a financial relationship with UpToDate, and research funding to his institution from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, and Sanofi.


Bergh J et al. ASCO 2019, Abstract 501.